Design of Stomach Acid-Stable and Mucin-Binding Enzyme Polymer Conjugates

2017 ◽  
Vol 18 (2) ◽  
pp. 576-586 ◽  
Author(s):  
Chad S. Cummings ◽  
Alan S. Campbell ◽  
Stefanie L. Baker ◽  
Sheiliza Carmali ◽  
Hironobu Murata ◽  
...  
1987 ◽  
Vol 114 (1) ◽  
pp. 18-26 ◽  
Author(s):  
Chohei Shigeno ◽  
Itsuo Yamamoto ◽  
Shegiharu Dokoh ◽  
Megumu Hino ◽  
Jun Aoki ◽  
...  

Abstract. We have partially purified a tumour factor capable of stimulating both bone resorption in vitro and cAMP accumulation in osteoblastic ROS 17/2 cells from three human tumours associated with humoral hypercalcaemia of malignancy. Purification of tumour factor by sequential acid urea extraction, gel filtration and cation-exchange chromatography, reverse-phase high performance liquid chromatography followed by analytical isoelectric focussing provided a basic protein (pI > 9.3) with a molecular weight of approximately 13 000 as a major component of the final preparation which retained both the two bioactivities. Bone resorbing activity and cAMP-increasing activity in purified factor correlated with each other. cAMP-increasing activity of the factor was heat- and acid-stable, but sensitive to alkaline ambient pH. Treatment with trypsin destroyed cAMP-increasing activity of the factor. Synthetic parathyroid hormone (PTH) antagonist, human PTH-(3– 34) completely inhibited the cAMP-increasing activity of the factor. The results suggest that this protein factor, having its effects on both osteoclastic and osteoblastic functions, may be involved in development of enhanced bone resorption in some patients with humoral hypercalcaemia of malignancy.


1984 ◽  
Vol 104 (4_Supplb) ◽  
pp. S91-S92
Author(s):  
G. DAXENBICHLER ◽  
E. H. MOSER
Keyword(s):  
Rat Lung ◽  

Author(s):  
Neeraj Agrawal ◽  
M.J. Chandrasekar ◽  
U.V. Sara ◽  
Rohini A.

A macromolecular prodrug of didanosine (ddI) for oral administration was synthesized and evaluated for in-vitro drug release profile. Didanosine was first coupled to 2-hydroxy ethyl methacrylate (HEMA) through a succinic spacer to form HEMA-Suc-ddI monomeric conjugate which was subsequently polymerized to yield Poly(HEMA-Suc-ddI) conjugate. The structures of the synthesized compounds were characterized by FT-IR, Mass and 1H-NMR spectroscopy. The prodrug was subjected for in-vitro drug release studies in buffers of pH 1.2 and 7.4 mimicking the upper and lower GIT. The results showed that the drug release from the polymeric backbone takes place in a sustained manner over a period of 24 h and the amount of drug released was comparatively higher at pH 7.4 indicating that the drug release takes place predominantly at the alkaline environment of the lower GIT rather than at the acidic environment of the upper GIT. This pH dependent sustained drug release behavior of the prodrug may be capable of reducing the dose limiting toxicities by maintaining the plasma drug level within the therapeutic range and increasing t1/2 of ddI. Moreover, the bioavailability of the drug should be improved as the prodrug releases ddI predominantly in the alkaline environment which will reduce the degradation of ddI in the stomach acid.


2013 ◽  
Vol 4 (1) ◽  
pp. 61-67 ◽  
Author(s):  
Cristina Cepraga ◽  
Thibault Gallavardin ◽  
Sophie Marotte ◽  
Pierre-Henri Lanoë ◽  
Jean-Christophe Mulatier ◽  
...  

2020 ◽  
Vol 378 (2) ◽  
Author(s):  
Fan Xiao ◽  
Zixiang Wei ◽  
Maggie Wang ◽  
Alexandra Hoff ◽  
Ying Bao ◽  
...  

2021 ◽  
pp. 2100008
Author(s):  
Hamilton Kakwere ◽  
Hua Zhang ◽  
Elizabeth S. Ingham ◽  
Marina Nura‐Raie ◽  
Spencer K. Tumbale ◽  
...  

Author(s):  
Kenny W.J. Chua ◽  
Jia Huan Liew ◽  
Clare L. Wilkinson ◽  
Amirrudin B. Ahmad ◽  
Heok Hui Tan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document